A year after President Donald Trump returned to office, federal rules governing the abortion pill mifepristone remain unchanged yet the political and regulatory environment around the drug is growing increasingly uncertain.
The FDA’s ongoing safety review, renewed legal battles, and intensifying anti-abortion rhetoric from activists and administration officials have introduced new risks to a $6.9 billion market heavily dependent on telehealth consultations and mail delivery. At the same time, drugmakers such as Danco Laboratories and GenBioPro are expanding into miscarriage care and hormonal treatments as they prepare for potential policy shifts.
Federal rules unchanged, but pressure is building
“For medication abortion, there haven’t been major federal policy changes yet,” said Katie O’Connor of the National Women’s Law Center. “But we’ve seen signals that something could be coming.”
Mifepristone — used with misoprostol in a two-drug regimen that accounts for roughly two-thirds of U.S. abortions — can still be prescribed through telemedicine and shipped by mail, within the limits of state law. Manufacturing has not slowed under Trump, and the FDA quietly approved a new generic version from Evita Solutions in September, the first new U.S. producer in five years.
Still, analysts warn that even minor regulatory adjustments could cascade through the supply chain, disrupting reimbursement, pharmacy compliance, and telehealth access.
The FDA review and Comstock revival possibilities
Trump-appointed FDA officials have shown sympathy toward anti-abortion groups, and the agency’s safety review initiated at the request of HHS Secretary Robert F. Kennedy Jr. could lead to stricter prescribing rules or even a withdrawal of the drug.
Outside the FDA, the administration could also attempt to revive the long-dormant Comstock Act, which prohibits mailing “obscene” materials, to restrict abortion pill shipments nationwide. The Biden administration interpreted the law narrowly, but a Trump Justice Department could reverse that position.
Industry responses: diversifying and litigating
Drugmakers appear to be preparing for turbulence. Danco is seeking approval to add miscarriage treatment to mifepristone’s label. Evita Solutions and GenBioPro are exploring hormonal therapies that could broaden their portfolios.
GenBioPro is still fighting a legal battle with West Virginia and the FDA over whether federal approval should override state bans a high-stakes test of federal preemption that could shape future challenges if telehealth access is restricted.
State-level shifts: uneven access and heightened enforcement
While no new state has passed a medication-abortion ban since Trump’s election, enforcement of existing laws has tightened in several conservative states. Texas, Louisiana, and Idaho have increased penalties for mailing abortion pills, and Texas’s “bounty-hunter” statute allows citizens to sue anyone who helps facilitate an illegal abortion.
Although enforcing mail bans is difficult the U.S. Postal Service does not screen for abortion pills the threat of prosecution has deterred many telehealth providers from prescribing across state lines.